Completed PHASE2 INTERVENTIONAL 2-arm NCT04687514

Effects of Glucagon-Like Peptide-1 Analogs on Sexuality (DESIRE)

Effects of Glucagon-Like Peptide-1 Analogs on Sexuality - a Randomized, Double-blind, Placebo-controlled Trial With Crossover Design

Sponsor: Goldschmidt-Jacobson Foundation

Conditions Sexual Functioning

Interventions Dulaglutide Placebo

Updated 7 times since 2021 Last updated: Sep 5, 2022 Started: May 5, 2021 Primary completion: Sep 5, 2022 Completion: Sep 5, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04687514, this PHASE2 trial focuses on Sexual Functioning and remains completed. Sponsored by Goldschmidt-Jacobson Foundation, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2021 — Apr 2022 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Mar 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Goldschmidt-Jacobson Foundation
Swiss National Science Foundation
University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland